Favorable Effect of Anti-TNF Therapy on Insulin Sensitivity in Nonobese, Nondiabetic Patients with Inflammatory Bowel Disease
Background. The aim of this study was to investigate the effect of anti-TNF therapy on glucose and lipid metabolism in nondiabetic, nonobese patients with inflammatory bowel disease (IBD). Patients and Methods. We studied 44 patients with IBD, without a known history of diabetes. Three of the patien...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | International Journal of Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2018/6712901 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850104543443943424 |
|---|---|
| author | Stavroula A. Paschou Fotios Kothonas Apostolos Lafkas Alexandros Myroforidis Vasiliki Loi Thomais Terzi Olympia Karagianni Androniki Poulou Konstantinos Goumas Andromachi Vryonidou |
| author_facet | Stavroula A. Paschou Fotios Kothonas Apostolos Lafkas Alexandros Myroforidis Vasiliki Loi Thomais Terzi Olympia Karagianni Androniki Poulou Konstantinos Goumas Andromachi Vryonidou |
| author_sort | Stavroula A. Paschou |
| collection | DOAJ |
| description | Background. The aim of this study was to investigate the effect of anti-TNF therapy on glucose and lipid metabolism in nondiabetic, nonobese patients with inflammatory bowel disease (IBD). Patients and Methods. We studied 44 patients with IBD, without a known history of diabetes. Three of the patients were diagnosed with overt diabetes and were excluded. Eighteen of the remaining patients (9 M/9 F, 33.6 ± 8.8 years) were on anti-TNF therapy for longer than 1 year, while 23 patients (16 M/7 F, 38.7 ± 12.5 years) were treated with aminosalicylates (AMSs). Twelve of the patients from the second group were then treated with anti-TNF and reassessed 6 months later. Fasting glucose, insulin, c-peptide, HbA1c, lipid, CRP, and fibrinogen levels were determined, and HOMA-IR index was calculated in all patients. Results. Patients from the two therapy groups were matched for age and BMI and were not obese. We did not find any differences between patients from the two therapy groups regarding fasting glucose, c-peptide, HbA1c, total cholesterol, HDL, LDL, triglycerides, CRP, and HOMA-IR index. In patients who were treated for 6 months with anti-TNF, a statistically significant decrease in insulin (before 15.5 ± 5.9 versus after 9.9 ± 2.9 μIU/ml, p=0.042) and c-peptide (before 2.4 ± 1 versus after 1.3 ± 0.4 ng/ml, p=0.030) levels as well as the HOMA-IR index (before 4.2 ± 1.9 versus after 2.2 ± 0.9, p=0.045) was observed, without any changes in weight, BMI, glucose, HbA1c, lipid, CRP, and fibrinogen levels. Conclusion. Anti-TNF therapy exerts a favorable effect on insulin sensitivity, while it has no effect on lipid levels in nondiabetic, nonobese patients with inflammatory bowel disease. |
| format | Article |
| id | doaj-art-46e55ddf7ad34a25bd99142a02ea6746 |
| institution | DOAJ |
| issn | 1687-8337 1687-8345 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Endocrinology |
| spelling | doaj-art-46e55ddf7ad34a25bd99142a02ea67462025-08-20T02:39:19ZengWileyInternational Journal of Endocrinology1687-83371687-83452018-01-01201810.1155/2018/67129016712901Favorable Effect of Anti-TNF Therapy on Insulin Sensitivity in Nonobese, Nondiabetic Patients with Inflammatory Bowel DiseaseStavroula A. Paschou0Fotios Kothonas1Apostolos Lafkas2Alexandros Myroforidis3Vasiliki Loi4Thomais Terzi5Olympia Karagianni6Androniki Poulou7Konstantinos Goumas8Andromachi Vryonidou9Department of Endocrinology and Diabetes, Hellenic Red Cross Hospital, Athens, GreeceDepartment of Gastroenterology, Hellenic Red Cross Hospital, Athens, GreeceDepartment of Endocrinology and Diabetes, Hellenic Red Cross Hospital, Athens, GreeceDepartment of Gastroenterology, Hellenic Red Cross Hospital, Athens, GreeceDepartment of Endocrinology and Diabetes, Hellenic Red Cross Hospital, Athens, GreeceDepartment of Endocrinology and Diabetes, Hellenic Red Cross Hospital, Athens, GreeceDepartment of Endocrinology and Diabetes, Hellenic Red Cross Hospital, Athens, GreeceDepartment of Gastroenterology, Hellenic Red Cross Hospital, Athens, GreeceDepartment of Gastroenterology, Hellenic Red Cross Hospital, Athens, GreeceDepartment of Endocrinology and Diabetes, Hellenic Red Cross Hospital, Athens, GreeceBackground. The aim of this study was to investigate the effect of anti-TNF therapy on glucose and lipid metabolism in nondiabetic, nonobese patients with inflammatory bowel disease (IBD). Patients and Methods. We studied 44 patients with IBD, without a known history of diabetes. Three of the patients were diagnosed with overt diabetes and were excluded. Eighteen of the remaining patients (9 M/9 F, 33.6 ± 8.8 years) were on anti-TNF therapy for longer than 1 year, while 23 patients (16 M/7 F, 38.7 ± 12.5 years) were treated with aminosalicylates (AMSs). Twelve of the patients from the second group were then treated with anti-TNF and reassessed 6 months later. Fasting glucose, insulin, c-peptide, HbA1c, lipid, CRP, and fibrinogen levels were determined, and HOMA-IR index was calculated in all patients. Results. Patients from the two therapy groups were matched for age and BMI and were not obese. We did not find any differences between patients from the two therapy groups regarding fasting glucose, c-peptide, HbA1c, total cholesterol, HDL, LDL, triglycerides, CRP, and HOMA-IR index. In patients who were treated for 6 months with anti-TNF, a statistically significant decrease in insulin (before 15.5 ± 5.9 versus after 9.9 ± 2.9 μIU/ml, p=0.042) and c-peptide (before 2.4 ± 1 versus after 1.3 ± 0.4 ng/ml, p=0.030) levels as well as the HOMA-IR index (before 4.2 ± 1.9 versus after 2.2 ± 0.9, p=0.045) was observed, without any changes in weight, BMI, glucose, HbA1c, lipid, CRP, and fibrinogen levels. Conclusion. Anti-TNF therapy exerts a favorable effect on insulin sensitivity, while it has no effect on lipid levels in nondiabetic, nonobese patients with inflammatory bowel disease.http://dx.doi.org/10.1155/2018/6712901 |
| spellingShingle | Stavroula A. Paschou Fotios Kothonas Apostolos Lafkas Alexandros Myroforidis Vasiliki Loi Thomais Terzi Olympia Karagianni Androniki Poulou Konstantinos Goumas Andromachi Vryonidou Favorable Effect of Anti-TNF Therapy on Insulin Sensitivity in Nonobese, Nondiabetic Patients with Inflammatory Bowel Disease International Journal of Endocrinology |
| title | Favorable Effect of Anti-TNF Therapy on Insulin Sensitivity in Nonobese, Nondiabetic Patients with Inflammatory Bowel Disease |
| title_full | Favorable Effect of Anti-TNF Therapy on Insulin Sensitivity in Nonobese, Nondiabetic Patients with Inflammatory Bowel Disease |
| title_fullStr | Favorable Effect of Anti-TNF Therapy on Insulin Sensitivity in Nonobese, Nondiabetic Patients with Inflammatory Bowel Disease |
| title_full_unstemmed | Favorable Effect of Anti-TNF Therapy on Insulin Sensitivity in Nonobese, Nondiabetic Patients with Inflammatory Bowel Disease |
| title_short | Favorable Effect of Anti-TNF Therapy on Insulin Sensitivity in Nonobese, Nondiabetic Patients with Inflammatory Bowel Disease |
| title_sort | favorable effect of anti tnf therapy on insulin sensitivity in nonobese nondiabetic patients with inflammatory bowel disease |
| url | http://dx.doi.org/10.1155/2018/6712901 |
| work_keys_str_mv | AT stavroulaapaschou favorableeffectofantitnftherapyoninsulinsensitivityinnonobesenondiabeticpatientswithinflammatoryboweldisease AT fotioskothonas favorableeffectofantitnftherapyoninsulinsensitivityinnonobesenondiabeticpatientswithinflammatoryboweldisease AT apostoloslafkas favorableeffectofantitnftherapyoninsulinsensitivityinnonobesenondiabeticpatientswithinflammatoryboweldisease AT alexandrosmyroforidis favorableeffectofantitnftherapyoninsulinsensitivityinnonobesenondiabeticpatientswithinflammatoryboweldisease AT vasilikiloi favorableeffectofantitnftherapyoninsulinsensitivityinnonobesenondiabeticpatientswithinflammatoryboweldisease AT thomaisterzi favorableeffectofantitnftherapyoninsulinsensitivityinnonobesenondiabeticpatientswithinflammatoryboweldisease AT olympiakaragianni favorableeffectofantitnftherapyoninsulinsensitivityinnonobesenondiabeticpatientswithinflammatoryboweldisease AT andronikipoulou favorableeffectofantitnftherapyoninsulinsensitivityinnonobesenondiabeticpatientswithinflammatoryboweldisease AT konstantinosgoumas favorableeffectofantitnftherapyoninsulinsensitivityinnonobesenondiabeticpatientswithinflammatoryboweldisease AT andromachivryonidou favorableeffectofantitnftherapyoninsulinsensitivityinnonobesenondiabeticpatientswithinflammatoryboweldisease |